Compugen Goes for Dual Listing on the Tel Aviv Stock Exchange | GenomeWeb

NEW YORK, Dec. 26 – Compugen, an Israeli bioinformatics company that trades on the Nasdaq stock exchange, said Wednesday that it had received approval to list its shares on the Tel Aviv Stock Exchange.

The move towards a dual listing is aimed at increasing interest in Compugen’s stock by providing easier access for investors in Israel to trade the company’s shares.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The final text of the bill to reauthorize the America COMPETES Act might smooth over the differences between NSF and the House science committee, ScienceInsider says.

Four Republican lawmakers urge President-elect Donald Trump to keep Francis Collins as NIH director, Stat News reports.

In Genome Research this week: Platinum variant catalog, algorithmic strategy for upgrading fragmented assemblies, and more.

Sequencing of a 10,000-year-old mummy leads to its repatriation to the Fallon Paiute-Shoshone Tribe, Nature News reports.